Phio Pharmaceuticals (PHIO) EBT (2011 - 2026)

Phio Pharmaceuticals (PHIO) has reported EBT for 16 consecutive years, with -$4.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 91.04% year-over-year to -$4.1 million; the trailing twelve-month figure through Jun 2026 stood at -$13.0 million (down 87.28% YoY), and the FY2025 full-year result was -$8.8 million, down 22.95% from the prior year.
• EBT eased to -$4.1 million in Q2 2026 per PHIO's latest filing, from -$4.0 million in the prior quarter.
• Across five years, EBT topped out at -$1.5 million in Q3 2024 and bottomed at -$4.1 million in Q2 2026.
• Historically, EBT has averaged -$2.6 million across 5 years, with a median of -$2.5 million in 2022.
• The sharpest annual moves came in 2024 and 2026: EBT jumped 45.1% in 2024, then sank 146.98% in 2026.
• Over 5 years, EBT stood at -$2.7 million in 2022, then jumped by 30.44% to -$1.9 million in 2023, then increased by 14.06% to -$1.6 million in 2024, then sank by 51.29% to -$2.5 million in 2025, then slumped by 67.6% to -$4.1 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$4.1 million, -$4.0 million, and -$2.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.